PIEZO1 and channelopathy: In addition, pathogenic PIEZO1 Gain-of-Function15,18,19 or Loss-of-Function69 mutations can be introduced in the PIEZO1-HaloTag hiPSCs for disease modeling of human PIEZO1 channelopathies.